Anti-SARS-CoV-2 Nucleocapsid Protein [mBG17]
(Antibody
#211756)
-
PurposeRecombinant mouse monoclonal Anti-SARS-CoV-2 nucleocapsid protein antibody
-
Depositing Lab
-
Recommended Applications
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Recombinant Antibody | 211756-rAb | 100 µg of purified recombinant antibody | $250 * |
* Log in to view industry pricing.
Features
-
Source SpeciesM. musculus (mouse)
-
IsotypeIgG2a
-
Light Chain Typekappa
-
Amino Acid Sequences
Sequences (2) — Accept Affinity Reagent Sequence Policy
Production & Usage
-
Antigen PlasmidpLVX-EF1alpha-SARS-CoV-2-N-2xStrep-IRES-Puro
-
PurificationPurification from cell culture supernatant using affinity chromatography followed by buffer exchange with centrifugal columns.
-
Storage BufferPBS + 1 mM sodium azide
Delivery
-
Concentration0.9–1.1 mg/mL
-
StorageUpon receipt, prepare single use aliquots and store at -20 °C until use. Avoid multiple freeze thaw cycles.
-
ShipmentBlue ice or room temp
Resource Information
-
Persistent Resource IdentifierRRID:AB_3083605
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Zeocin® is an InvivoGen trademark.
Trademarks:
Target Antigen
Protein | Nucleoprotein |
---|---|
Antigen Description | Amino acids 133–419 of the SARS-CoV-2 (isolate USA-WA1/2020) N protein with a N-terminal T7 leader sequence to improve translation efficiency |
Antigen Amino Acid Sequence |
|
Epitope | Amino acids 381-419 |
Epitope Amino Acid Sequence |
|
Species | Other |
Gene | N |
Alternative Names |
|
External References |
|
Applications (1)
Western Blot
These antibodies were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the antibodies were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
Anti-SARS-CoV-2 Nucleocapsid Protein [mBG17] - from Brian Geiss (Addgene antibody # 211756 ; http://n2t.net/addgene:211756 ; RRID:AB_3083605) -
For your References section:
Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody. Terry JS, Anderson LB, Scherman MS, McAlister CE, Perera R, Schountz T, Geiss BJ. Virology. 2021 Jun;558:28-37. doi: 10.1016/j.virol.2021.01.003. Epub 2021 Feb 1. 10.1016/j.virol.2021.01.003 PubMed 33714753